<DOC>
	<DOC>NCT03008616</DOC>
	<brief_summary>This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.</brief_summary>
	<brief_title>Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects With Severe Preeclampsia</brief_title>
	<detailed_description />
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Fetal gestational age 23 0/7 to 31 6/7 weeks Treated with expectant management Meets ACOG criteria for severe preeclampsia Willing and able to provide written, informed consent Decision to deliver within 24 hours has been made Weight &gt; 150 kg Eclampsia Significant antecedent obstetrical problems Clinically significant fetal anomaly or chromosomal abnormalities Chronic renal disease Active hepatic disease, antiphospholipid antibody syndrome, or lupus Unstable medical or psychiatric disorder Need for use of digitalis like products History of anaphylactic allergic reactions Prior use of antibodies/fab fragments from sheep Serum creatinine ≥ 2.0 mg/dL Platelet count &lt; 50,000 Pulmonary edema Estimated fetal weight &lt; 5th percentile</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>